Capecitabine

Discontinued Product

Capecitabine (Cat. No. 4799) has been withdrawn from sale for commercial reasons.
Description: Prodrug of 5-Fluorouracil (Cat. No. 3257). Inhibits DNA synthesis
Alternative Names: Ro 09-1978
Chemical Name: 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews (1)
Literature (2)

Biological Activity for Capecitabine

Capecitabine is a prodrug of 5-Fluorouracil (5-FU) (Cat. No. 3257). Selectively activated in tumor cells by thymidine phosphorylase; inhibits DNA synthesis upon conversion to 5-FU. Orally available.

Compound Libraries for Capecitabine

Capecitabine is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Capecitabine

M. Wt 359.35
Formula C15H22FN3O6
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 154361-50-9
PubChem ID 60953
InChI Key GAGWJHPBXLXJQN-UORFTKCHSA-N
Smiles C[C@H]1O[C@@H](N2C=C(F)C(NC(OCCCCC)=O)=NC2=O)[C@H](O)[C@@H]1O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Capecitabine

Certificate of Analysis / Product Datasheet
Select another batch:

References for Capecitabine

References are publications that support the biological activity of the product.

Shimma et al (2000) The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. Bioorg.Med.Chem.Lett. 8 1697 PMID: 10976516

Desmoulin et al (2002) Metabolism of capecitabine, an oral fluorou. prodrug: 19F NMR studies in animal models and human urine. Drug Metab.Dispos. 30 1221 PMID: 12386128

Bhuyan et al (1972) Cell cycle phase specificity of antitumor agents. Cancer Res. 32 398 PMID: 4258018

View Related Products by Target

View Related Products by Product Action

View all DNA, RNA and Protein Synthesis Inhibitors

Keywords: Capecitabine, Capecitabine supplier, 5-Fluorouracil, prodrugs, 5-FU, DNA, synthesis, inhibitors, inhibits, inhbits, anticancer, Ro09-1978, chemotherapeutics, Ro, 09-1978, DNA,, RNA, and, Protein, Synthesis, 4799, Tocris Bioscience

Citations for Capecitabine

Citations are publications that use Tocris products.

Currently there are no citations for Capecitabine.

Reviews for Capecitabine

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Capecitabine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Medium concentrations of capecitabine only weakly slow melanoma growth in vitro.
By Anonymous on 02/14/2019
Assay Type: In Vitro
Species: Human

Capecitabine was used at a 20 uM concentration for in vitro culture with SK-MEL-28 and cell viability was monitored over time with live imaging. Arrow indicates when compound was added to media.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cell Cycle and DNA Damage Research Product Guide

Cell Cycle and DNA Damage Research Product Guide

This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:

  • Cell Cycle and Mitosis
  • DNA Damage Repair
  • Targeted Protein Degradation
  • Ubiquitin Proteasome Pathway
  • Chemotherapy Targets
Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells